Inflammatix Secures $57 Million to Advance Novel Diagnostic for Patients with Suspected Infections or Sepsis
Our products are in development, are not for sale, and do not have marketing approval or clearance from regulatory authorities in any jurisdiction.
Interpreting the immune response, the TriVerity test informs on key clinically actionable questions:
- Does the patient have a bacterial or viral infection or a noninfectious condition?
- Is the patient likely to need ICU-level intervention?
The power of the immune response to diagnose acute infections and sepsis
Emergency departments across the US routinely see patients suspected of acute infection and sepsis
In up to half of these patients, physicians struggle to make proper diagnosis and prognosis and would welcome novel tools to assist them.1
IMMUNE RESPONSE
Expertise in interpreting the immune response
Inflammatix host response diagnostics are powered by ‘reading’ the immune system. Our immune system has developed targeted responses to different types of infections and other diseases over millions of years of evolution.
Leveraging our expertise in bioinformatics, including machine learning and artificial intelligence, and molecular biology, we are harnessing the ability to interpret the immune response to develop tests aimed to help physicians make confident and timely clinical decisions.
Most infections are locally contained and do not penetrate into the bloodstream. This makes pathogen-targeting tests insensitive for infections. Immune cells fight the infection locally and then circulate into the blood, where we can measure their ‘signatures’ using mRNA profiles.